The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The interplay between Tumor Protein TROP2 (TACSTD2) and PD-L1 in lung adenocarcinoma (LUAD) is crucial for drug resistance and immunotherapy effectiveness but remains poorly understood.
• Understanding these interactions is vital for developing targeted therapies and improving patient outcomes in LUAD.

Purpose of the Study:

• To investigate the relationship between TACSTD2 and PD-L1 expression in LUAD.
• To elucidate the molecular mechanisms and tumor microenvironment dynamics associated with TROP2 and PD-L1.
• To identify potential diagnostic markers and therapeutic strategies for LUAD.

Main Methods:

• Transcriptome analysis of lung cancer cell lines (PC9 parental and drug-resistant variants).
• Immunohistochemistry on tumor tissues and immune cells.
• Single-cell RNA sequencing (scRNA-seq) for detailed cellular analysis.
• Gene ontology analysis for pathway enrichment.

Main Results:

• TACSTD2 expression strongly correlates with poor clinical outcomes, especially in immunotherapy-treated patients (HR 1.71 for OS, 2.95 for PFS).
• Transcriptome analysis revealed resistance mechanisms involving MAPK signaling and immune receptor regulation.
• Elevated TROP2 in tumor tissues, particularly in PD-L1 positive specimens, with negative correlation to CD8+ T cell infiltration and positive correlation to cancer-associated fibroblasts.
• scRNA-seq identified two distinct cancer subtypes with differential TACSTD2 expression, linked to cell adhesion and immune interaction pathways.

Conclusions:

• TACSTD2 and PD-L1 expression significantly influence LUAD progression and treatment response.
• Findings highlight TROP2's role in mediating drug resistance and shaping the tumor immune microenvironment.
• This study provides insights into novel diagnostic markers and therapeutic strategies targeting TROP2 and PD-L1 in LUAD.